Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
Conditions: Cholangiocarcinoma; Chondrosarcoma; GliomaIntervention: Drug: AG881Sponsor: Agios Pharmaceuticals, Inc.Recruiting - verified June 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Bile Duct Cancer | Brain Tumor | Cholangiocarcinoma | Chondrosarcoma | Glioma | Research | Study